EUVIMEDEUVIMED entdecken
Crossref

Utility of multigene panel next‐generation sequencing in routine clinical practice for identifying genomic alterations in newly diagnosed metastatic nonsmall cell lung cancer

Udit Nindra iD, Abhijit Pal iD, Victoria Bray, Po Y Yip, Annette Tognela, Tara L Roberts, Therese M Becker, Jonathon Williamson, Mahtab Farzin, Jing J Li, Vivienne Lea, Abeer Hagelamin und 4 weitere

Internal Medicine Journal · 2024

DOI: 10.1111/imj.16224 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Internal Medicine Journal, 2024. Verfasst von Udit Nindra und 15 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Oncology, Liverpool Hospital, Sydney, New South Wales, Australia. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Lung Neoplasms. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 8 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

The standard of care in newly diagnosed metastatic non‐small cell lung cancer (NSCLC) is to test for aberrations in three genes for driver mutations – ALK, ROS1 and epidermal growth factor receptor (EGFR) – and also for immunohistochemistry to be performed for programmed death‐ligand 1 expression level. Next‐generation sequencing (NGS), with or without RNA fusion testing, is increasingly used in standard clinical practice to identify patients with potentially actionable mutations. Stratification of NGS mutation tiers is currently based on the European Society of Medical Oncology Scale for Clinical Actionability of Molecular Targets (ESCAT) Tiers I–V and X.

Aim

Our aim was to analyse NSCLC tumour samples for the prevalence of Tiers I–V mutations to establish guidance for current and novel treatments in patients with metastatic disease.

Methods

NGS was performed employing the Oncomine Precision Assay (without RNA fusion testing) that interrogates DNA hotspot variants across 45 genes to screen 210 NSCLC tissue samples obtained across six Sydney hospitals between June 2021 and March 2022.

Results

In our cohort, 161 of 210 (77%) had at least one gene mutation identified, with 41 of 210 (20%) having two or more concurrent mutations. Tier I mutations included 42 of 210 (20%) EGFR mutations (EIA) and five of 210 (3%) MET exon 14 skipping mutations (EIB). Non‐Tier I variants included 22 of 210 (11%) KRAS G12C hotspot mutations (EIIB), with a further 47 of 210 (22%) having non‐ G12C KRAS (EX) mutations. NGS testing revealed an additional 15% of cases with Tier II ESCAT mutations in NSCLC. Forty‐six percent of patients also demonstrated potential Tier III and IV mutations that are currently under investigation in early‐phase clinical trials.

Conclusions

In addition to identifying patients with genomic alterations suitable for clinically proven standard‐of‐care therapeutic options, the 45‐gene NGS panel has significant potential in identifying potentially actionable non‐Tier 1 mutations that may become future standard clinical practice in NSCLC.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Non-Small-Cell LungLung NeoplasmsHumansProtein-Tyrosine KinasesProto-Oncogene Proteins p21(ras)Proto-Oncogene ProteinsGenomicsMutationErbB ReceptorsHigh-Throughput Nucleotide SequencingRNA

Stichwörter der Autor:innen

actionable mutationnext‐generation sequencingnon‐small cell lung cancerprecision oncology

Substanzen

Protein-Tyrosine KinasesProto-Oncogene Proteins p21(ras)Proto-Oncogene ProteinsErbB ReceptorsRNA

Autor:innen und Institutionen

  • Department of Medical Oncology, Liverpool Hospital, Sydney, New South Wales, Australia.
  • Department of Medical Oncology, Macarthur Cancer Therapy Centre, Campbelltown Hospital, Sydney, New South Wales, Australia.
  • Department of Medical Oncology, Bankstown-Lidcombe Hospital, Sydney, New South Wales, Australia.
  • Ingham Institute for Applied Medical Research, Sydney, New South Wales, Australia.
  • Discipline of Pathology, School of Medicine, Western Sydney University, Sydney, New South Wales, Australia.
  • South Western Clinical School, University of New South Wales, Sydney, New South Wales, Australia.

ORCID-Profile: Udit Nindra, Abhijit Pal

Zitieren

APA

Nindra, U., Pal, A., Bray, V., Yip, P. Y., Tognela, A., Roberts, T. L., Becker, T. M., Williamson, J., Farzin, M., Li, J. J., Lea, V., Hagelamin, A., Ng, W., Wang, B., Lee, C. S., & Chua, W. (2024). Utility of multigene panel next‐generation sequencing in routine clinical practice for identifying genomic alterations in newly diagnosed metastatic nonsmall cell lung cancer. Internal Medicine Journal. https://doi.org/10.1111/imj.16224

Vancouver

Nindra U, Pal A, Bray V, Yip PY, Tognela A, Roberts TL, et al. Utility of multigene panel next‐generation sequencing in routine clinical practice for identifying genomic alterations in newly diagnosed metastatic nonsmall cell lung cancer. Internal Medicine Journal. 2024. doi:10.1111/imj.16224

BibTeX
@article{Nindra2024,
  author = {Nindra, Udit and Pal, Abhijit and Bray, Victoria and Yip, Po Y and Tognela, Annette and Roberts, Tara L and Becker, Therese M and Williamson, Jonathon and Farzin, Mahtab and Li, Jing J and Lea, Vivienne and Hagelamin, Abeer and Ng, Weng and Wang, Bin and Lee, C Soon and Chua, Wei},
  title = {Utility of multigene panel next‐generation sequencing in routine clinical practice for identifying genomic alterations in newly diagnosed metastatic nonsmall cell lung cancer},
  journal = {Internal Medicine Journal},
  year = {2024},
  doi = {10.1111/imj.16224}
}
Kostenlos starten →